Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial - 29/08/11
Doi : 10.1067/S0022-3476(03)00388-3
Philip J. Hashkes, MD, MSc, Tsivia Tauber, MD, Eli Somekh, MD, Riva Brik, MD, Judith Barash, MD, Masza Mukamel, MD, Liora Harel, MD, Abraham Lorber, MD, Matityahu Berkovitch, MD, Yosef Uziel, MD, MSc ⁎ 
From Sieff and Poriya Hospitals, Safed and Tiberias, Assaf Harofeh Hospital, Zerifin, Wolfson Hospital, Holon, Rambam Medical Center, Haifa, Kaplan Medical Center, Rehovot, Schneider Children's Hospital, Petah-Tikva, and Sapir Medical Center, Kfar-Saba, Israel
Reprint requests: Yosef Uziel, MD, MSc, Pediatric Rheumatology, Sapir Medical Center, Kfar-Saba, Israel 44281.for the Pediatric Rheumatology Study Group of Israel
Abstract |
We performed a prospective, randomized, open-label equivalence study comparing the use of naproxen to aspirin in 33 patients with rheumatic fever. The mean time until resolution of arthritis was 2.9±2.9 days in both groups. Liver enzyme elevations were more frequent in the aspirin group (P=.002). We conclude that naproxen is as effective, is easier to use, and is safer than aspirin in the treatment of the arthritis of rheumatic fever.
Le texte complet de cet article est disponible en PDF.Abbreviations : ASA, ESR, NSAID, NXN, RF
Plan
 | Supported in part by grant no. S/4507 from the Chief Scientist's Office of the Ministry of Health, Israel. |
© 2003
Mosby, Inc. Tous droits réservés.
Vol 143 - N° 3
P. 399-401 - septembre 2003 Retour au numéro
Article précédent
- Recurrent infections in a nine-month-old male infant
- Michael Palumbo, Robert A Good, Nutthapong Tangsinmankong
- Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency
- Zubin Punthakee, Laurent Legault, Constantin Polychronakos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?